I do not know of any scheme/plan/approach that ahead of time would determine accurately and unequivocally if eculizumab would work. Having a low C4 and/or C3 serum level would suggest that the APLS antibodies are fixing complement. In other words, complement activation may be contributing to the pat...

Eculizumab is a monoclonal antibody that binds to C5 and inhibits activation of the membrane attack complex which plays an important role in the pathogenesis of APLS. It is currently approved to treat atypical HUS, a condition that causes thrombotic microangiopathy. There are several case reports an...